Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | -2.68% | -12.70% | +100.00% |
05-14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.00% | 41.34M | |
+31.61% | 49.46B | |
+1.01% | 42.58B | |
+48.88% | 42.49B | |
-5.26% | 29.09B | |
+12.48% | 26.61B | |
-23.61% | 18.64B | |
+7.22% | 13.16B | |
+30.84% | 12.55B | |
+23.68% | 12.1B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target